Your browser doesn't support javascript.
loading
Current Industry Best Practice on in-use Stability and Compatibility Studies for Biological Products.
Blümel, Markus; Liu, Jing; de Jong, Isabella; Weiser, Sarah; Fast, Jonas; Litowski, Jennifer; Shuman, Melissa; Mehta, Shyam B; Amery, Leanne; Tan, David Cheng Thiam; Jia, Feng; Shekhawat, Dushyant; Dagallier, Camille; Emamzadeh, Mina; Medina, Annette; Santos, Camilla; Gasser, Florian; Urban, Christian.
Afiliação
  • Blümel M; Novartis Pharma AG, Biologics Analytical Development, Lichtstrasse 35, CH-4056 Basel, Switzerland. Electronic address: markus.bluemel@novartis.com.
  • Liu J; Seagen Inc., Pharmaceutical Sciences, 21717 30th Drive S.E., Building 3. Bothell, WA, 98021, USA. Electronic address: liujing97@gmail.com.
  • de Jong I; Genentech (A Member of the Roche Group), Pharmaceutical Development, 1 DNA Way, South San Francisco, CA, 94080, USA.
  • Weiser S; Pfizer; Biotherapeutics Pharmaceutical Sciences, 1 Burtt Road, Andover, MA 01810, USA.
  • Fast J; F. Hoffmann-La Roche Ltd., Pharmaceutical Development & Supplies, PTD Biologics Europe, Grenzacherstrasse 124, CH, 4070 Basel, Switzerland.
  • Litowski J; Amgen Inc., Process Development, 360 Binney St., Cambridge, MA, 02141, USA.
  • Shuman M; GSK, Strategic External Development, Sterile Drug Product Operations, 1250 S. Collegeville Road Collegeville, PA, 19426, USA.
  • Mehta SB; Teva Branded Pharmaceutical Products, Drug Product Development and Operations, 145 Brandywine Pkwy, West Chester, PA 19380, USA.
  • Amery L; AstraZeneca, Dosage Form Design and Development, Aaron Klug Building, Granta Park, Cambridge, Cambridgeshire, CB21 6GH, UK.
  • Tan DCT; AbbVie Inc., North Chicago, IL, USA.
  • Jia F; Biogen, Biologics Drug Product, 225 Binney Street, Cambridge, MA, 02142, USA.
  • Shekhawat D; Eli Lilly and Company, Bioproduct Research and Development, Indianapolis, IN, 46285, USA.
  • Dagallier C; Sanofi, Biologics Drug Product Development, 1 impasse des ateliers, 94403 Vitry-Sur-Seine, France.
  • Emamzadeh M; AstraZeneca, Dosage Form Design and Development, Aaron Klug Building, Granta Park, Cambridge, Cambridgeshire, CB21 6GH, UK.
  • Medina A; AstraZeneca, Dosage Form Design and Development, One Medimmune Way, Gaithersburg, MD, 20878, USA.
  • Santos C; Amgen Inc., Product Quality, 40 Technology Way, West Greenwich, RI, 02817, USA.
  • Gasser F; Novartis Pharma AG, Biologics Analytical Development, Biochemiestrasse 10, 6336 Langkampfen, Austria.
  • Urban C; Sanofi, Biologics Drug Product Development, Industriepark Höchst, D-65926 Frankfurt am Main, Germany.
J Pharm Sci ; 112(9): 2332-2346, 2023 09.
Article em En | MEDLINE | ID: mdl-37160227
ABSTRACT
Evaluating the in-use stability of a biological product including its compatibility with administration components allows to define handling instructions and potential hold times that retain product quality during dose preparation and administration. The intended drug product usage may involve the dilution of drug formulation into admixtures for infusion and exposure to new interfaces of administration components like intravenous (iv) bags, syringes, and tubing. In-use studies assess the potential impact on product quality by simulating drug handling throughout the defined in-use period. Considering the wide range of in-use conditions and administration components available globally, only limited guidance is available from regulators on expected in-use stability data. A working group reviewed and consolidated industry approaches to assess physicochemical stability of traditional protein-based biological products during clinical development and for commercial use. The insights compiled in this review article can be leveraged across the industry and encompass topics such as representative drug product material and administration components, testing conditions, quality attributes evaluated and respective acceptance criteria, applied quality standards, and regulatory requirements. These practices may help companies in the study design, and they may inform discussions with global regulators.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Produtos Biológicos Tipo de estudo: Guideline Idioma: En Revista: J Pharm Sci Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Produtos Biológicos Tipo de estudo: Guideline Idioma: En Revista: J Pharm Sci Ano de publicação: 2023 Tipo de documento: Article